skip to content

Centre for Law, Medicine and Life Sciences

Faculty of Law
 
Read more at: Tickets still available for CeBIL Symposium 2021 - Orphan Drug Innovation: Needs and Priorities

Tickets still available for CeBIL Symposium 2021 - Orphan Drug Innovation: Needs and Priorities

6 September 2021

Tickets are still available to attend the CeBIL Annual Symposium 2021 - Orphan Drug Innovation: Needs and Priorities. Rare diseases affect approximately 25-30 million people in Europe, including millions of children. However, since each disease affects less than one person in every 2,000, the pharmaceutical industry has...


Read more at: Nature Biotechnology accepts paper from LML on new medical use patents

Nature Biotechnology accepts paper from LML on new medical use patents

2 September 2021

Nature Biotechnology has accepted a seventh article from LML’s empirical-based IP research group. Most countries active in pharmaceutical innovation offer patent protection and market exclusivity for new medical uses of known products. However, the question of whether such policies offer sustainable business models is an...


Read more at: LML published in International Review of Intellectual Property and Competition Law

LML published in International Review of Intellectual Property and Competition Law

20 July 2021

LML is pleased to announce that International Review of Intellectual Property and Competition Law has published 'Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the ‘‘+1’’ Regulatory Exclusivity' by John Liddicoat, Kathy Liddell, Mateo Aboy, and Jakob Wested. This paper forms part of...


Read more at: Registration open for Orphan Drug Symposium

Registration open for Orphan Drug Symposium

4 July 2021

LML is delighted to announce that registration has opened for the CeBIL Annual Symposium 2021 - Orphan Drug Innovation: Needs and Priorities. Rare diseases affect approximately 25-30 million people in Europe, including millions of children. However, since each disease affects less than one person in every 2,000, the...


Read more at: LML publishes article on cross-border transfers of health data in Journal of Law and the Biosciences

LML publishes article on cross-border transfers of health data in Journal of Law and the Biosciences

23 June 2021

LML is pleased to announce that the Journal of Law and the Biosciences has published ‘Standard contractual clauses for cross-border transfers of health data after Schrems II ’ , authored by Laura Bradford, Mateo Aboy, and Kathy Liddell. Standard contractual clauses (SCCs) have long been considered the most accessible...


Read more at: Dr Stevie Martin’s PhD Thesis Published by Routledge

Dr Stevie Martin’s PhD Thesis Published by Routledge

28 April 2021

LML is delighted to announce that Dr Stevie Martin’s PhD thesis, ‘Assisted Suicide and the European Convention on Human Rights’, has been published by Routledge. Locating assisted suicide within the broader medical end-of-life context and drawing on the empirical data available from the increasing number of permissive...


Read more at: Dr John Liddicoat participates in Seminar on Drug Repurposing

Dr John Liddicoat participates in Seminar on Drug Repurposing

27 April 2021

On 27 April 2021, Dr John Liddicoat (LML Senior Research Associate) participated in ‘Drug Repurposing in the EU – an Innovation Failure’. At this event, part of the Finnish IPR University Center’s Dialogue of Experts series, Dr Liddicoat elaborated on the findings of two forthcoming papers: ‘Has the EU Incentive for Drug...


Read more at: Dr John Liddicoat participates in panel discussion on novelty and repurposing drugs

Dr John Liddicoat participates in panel discussion on novelty and repurposing drugs

8 April 2021

On 8 April 2021, Dr John Liddicoat (LML Senior Research Associate) participated in a panel discussion on novelty and second medical use patents. Hosted by Life Sciences Intellectual Property Review, ‘Why patent protection is Key to Commercialising Repurposed Drugs’ was a roundtable event which sought to discuss how...


Read more at: Dr John Liddicoat selected as Thomas Edison Fellow

Dr John Liddicoat selected as Thomas Edison Fellow

26 March 2021

The Thomas Edison Innovation Law and Policy Fellowship is a year-long non-resident programme that brings together leading scholars to develop research on topical issues. The Edison Fellowship is one of the centrepieces of the Centre for the Protection of Intellectual Property's mission to promote a better academic...


Read more at: Dr John Liddicoat and James Parish Quoted in UK IPO Review of AI and IP

Dr John Liddicoat and James Parish Quoted in UK IPO Review of AI and IP

23 March 2021

Last year, the UK Government issued a call for views on artificial intelligence and IP. Dr John Liddicoat (Senior Research Associate) and Mr James Parish (CIPIL) made a short submission addressing AI inventorship. On 23 March 2021, the government published its response to the views it received. The government quoted Dr...